NeoGenomics enters its April 29 Q1 earnings release with a notable divergence between a surging stock price and a short position that has been quietly growing all month.
The price tells a recovery story: shares closed at $9.02 on April 28, up 25% over the past month and 13% on the week. Yet short interest has moved in the opposite direction. At 6.8% of the free float, the short position climbed 16% over the past week alone — from roughly 7.6 million shares to 8.8 million. That acceleration means new shorts have been added into the rally, a sign that not everyone is convinced the move is justified. Days to cover runs at 4.8, giving the short base meaningful exposure heading into the event.
Options positioning reinforces the cautious read. The put/call ratio jumped to 0.15 on April 28 — more than 2.5 standard deviations above its 20-day average of 0.12. That is the most defensively skewed the options market has been in months, and the move was abrupt: the ratio had sat near its 52-week low just weeks ago before flipping sharply on earnings week. The borrow market, however, sends a contrasting signal. Cost to borrow is a modest 0.47% and has drifted lower over the past month. Availability remains ample, suggesting no squeeze dynamic in the lending pool — shorts are not under pressure to cover on borrow alone.
The bull-bear divide is clear. Bulls point to improving unit economics: adjusted gross margin expanded 150 basis points year-on-year in Q4 2024, revenue per test rose to $459, and NGS testing revenue grew 18% in Q1 2025. That last data point is the crux — next-generation sequencing is the high-value growth engine, and consistent NGS gains are what justify multiple expansion from these levels. Bears flag the underperforming non-clinical sales line, which missed consensus by roughly 12% last reported, along with reimbursement risk and the margin drag from reinvestment. The consensus rating is a hold, with six analysts sitting neutral. The most recent target updates — from Piper Sandler raising to $13 and Needham to $15 in February — sit well above the current $9.02 price, suggesting analysts who are positive see meaningful room higher. But those targets date from before the latest quarter, and with the stock down sharply from those February levels, the gap reflects unresolved execution questions rather than a rerated opportunity.
The one institutional data point worth noting: First Trust Advisors entered the shareholder register in the most recent quarter, adding over 6.1 million shares to become the fifth-largest holder at 4.7% of shares outstanding — a sizable new position that adds support to the float picture.
The print will test whether NeoGenomics can demonstrate that the NGS growth trajectory is sustaining and that non-clinical revenue is stabilising — the two variables that most directly determine whether the stock's month-long re-rating holds or reverses.
See the live data behind this article on ORTEX.
Open NEO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
